Valneva recently announced what it described as positive topline results from the lot-to-lot phase-III trial of its single-shot Chikungunya vaccine candidate, VLA1553, saying the trial met its primary endpoint.
“Three consecutively manufactured vaccine lots elicited equivalent immune responses,” the company said in a statement, adding that it would kick-off proceedings to win regulatory approval by the US Food and Drug Administration (FDA) next year.
In August, after Valneva gave a positive update on the phase-III trial.
The lot-to-lot trial will continue towards a final six-month analysis with final trial results expected in the second quarter of 2022, the company said in a statement.
Edits by EP News Bureau